Trending...
- Tim O'Loughlin Appointed Chief Executive Officer of Vantiva and Co-opted as a Director of the Board
- project44 Secures Top Spot Across 12 Categories in G2 Fall 2024 Grid Reports
- Restoration Specialists Celebrates a Successful 2024 and Strong Q4
NAPERVILLE, Ill., Sept. 28, 2024 ~ Endotronix, a subsidiary of Edwards Lifesciences (NYSE: EW), has released the one-year clinical results from their PROACTIVE-HF study at the Heart Failure Society of America (HFSA) Annual Scientific Meeting. The study evaluated the outcomes of using the Cordella Pulmonary Artery (PA) Sensor System in managing heart failure.
The data from the study showed that out of the 456 patients who were managed with Cordella, there was a significant reduction in one-year hospitalizations and all-cause mortality rate. This was compared to the pre-specified rate of 70 events per 100 patients, with only 36 events per 100 patients being reported in the study. This represents a 49% decrease in hospitalizations and mortality.
In addition to these primary endpoints, the study also looked at secondary endpoints such as quality of life and biomarker reduction. The results showed significant improvements in these areas as well. Patients experienced a 10.5% increase in their Kansas City Cardiomyopathy Questionnaire score, a 13.3% improvement in their 6-minute walk test distance, and a 36.2% decrease in New York Heart Association classification. There was also a 5.7% reduction in NT-proBNP levels, which is a biomarker for heart failure.
More on illi News
These findings further validate the previously published six-month data on the safety and efficacy of using Cordella for managing heart failure.
Dr. Liviu Klein, Section Chief of Advanced Heart Failure at the University of California San Francisco and national principal investigator of PROACTIVE-HF trial, commented on these results saying, "These data are consistent and compelling validating that PA pressure-guided therapy improves heart failure outcomes." He also noted that this trial adds to our understanding of how comprehensive data can improve outcomes by allowing for remote medical adjustments and engaging patients in their own care.
The study showed that by optimizing guideline-directed medical therapy and diuretics, clinicians were able to reduce PA pressures in congested patients, leading to improved heart function. One unique aspect of Cordella is that it provides patients with visibility into their health data, which can help drive their engagement and compliance with treatment.
Endotronix, which was acquired by Edwards Lifesciences, focuses on the intersection of medical technology and digital health to improve care for heart failure patients. Their comprehensive Cordella solution allows for proactive and data-driven management of heart failure, leading to better outcomes. The Cordella Sensor is an implantable device that directly measures PA pressure, a key indicator of congestion in heart failure patients.
To learn more about Endotronix and their innovative solutions for managing heart failure, visit www.endotronix.com.
The data from the study showed that out of the 456 patients who were managed with Cordella, there was a significant reduction in one-year hospitalizations and all-cause mortality rate. This was compared to the pre-specified rate of 70 events per 100 patients, with only 36 events per 100 patients being reported in the study. This represents a 49% decrease in hospitalizations and mortality.
In addition to these primary endpoints, the study also looked at secondary endpoints such as quality of life and biomarker reduction. The results showed significant improvements in these areas as well. Patients experienced a 10.5% increase in their Kansas City Cardiomyopathy Questionnaire score, a 13.3% improvement in their 6-minute walk test distance, and a 36.2% decrease in New York Heart Association classification. There was also a 5.7% reduction in NT-proBNP levels, which is a biomarker for heart failure.
More on illi News
- Get an Online Handicap Parking Placard in Los Angeles: HandicapMD.com Revolutionizes Access to Handicap Placards
- 10th Annual Benefit for Women Veterans: 100 Pretty Purses to Mark 2,000 Lives Changed Since 2015
- Carl Resnick joins Flexible Plan Investments as vice president of national sales
- Project EverGreen Creates A Cooler, Greener Future for New York City's Joe Holzka Community Garden
- Gravesider Mobile App Wants to Hire Actors to Play Dead
These findings further validate the previously published six-month data on the safety and efficacy of using Cordella for managing heart failure.
Dr. Liviu Klein, Section Chief of Advanced Heart Failure at the University of California San Francisco and national principal investigator of PROACTIVE-HF trial, commented on these results saying, "These data are consistent and compelling validating that PA pressure-guided therapy improves heart failure outcomes." He also noted that this trial adds to our understanding of how comprehensive data can improve outcomes by allowing for remote medical adjustments and engaging patients in their own care.
The study showed that by optimizing guideline-directed medical therapy and diuretics, clinicians were able to reduce PA pressures in congested patients, leading to improved heart function. One unique aspect of Cordella is that it provides patients with visibility into their health data, which can help drive their engagement and compliance with treatment.
Endotronix, which was acquired by Edwards Lifesciences, focuses on the intersection of medical technology and digital health to improve care for heart failure patients. Their comprehensive Cordella solution allows for proactive and data-driven management of heart failure, leading to better outcomes. The Cordella Sensor is an implantable device that directly measures PA pressure, a key indicator of congestion in heart failure patients.
To learn more about Endotronix and their innovative solutions for managing heart failure, visit www.endotronix.com.
Filed Under: Business
0 Comments
Latest on illi News
- Integris Composites Displays New Military Armor at AUSA 2024
- Expert HVAC Upgrade Tips to Maximize Energy Efficiency
- ALLTRA SonicSwap Expands DeFi Opportunities with Weekly Listings and Global Partnerships
- ALL Mainnet Launches AUSDT Stablecoin onto the global arena
- The Giving Edge: Is Leveraging Outrageous Kindness the Missing Link for Corporate ROI?
- One Of The Largest Native American Burial Sites In The United States Moves A Step Closer To National Recognition
- Gene Siskel Film Center of The School of The Art Institute of Chicago Announces the Full Program for the 30th Annual Black Harvest Film Festival
- Mayor Brandon Johnson and London Tech Startup Announce Chicago as U.S. Headquarters, Bringing Well-being Benefits to Businesses Nationwide
- Cummings Graduate Institute for Behavioral Health Studies Announces New Book: Integrated Behavioral Health: Applying the Biodyne Mindset in Healthcare
- SureFlow to Showcase AI and Eco-Technology Energy Management Solutions at GITEX 2024
- Smart Merchant Solution goes BLUU to strengthen its position in the Point of Sale (POS) Solutions and Payments Processing Sector
- Local SF Conservatory Pre-College Student Selected to Perform at Carnegie Hall
- CU Aerospace, LLC Awarded Multi-Million Dollar Contract for Cutting-Edge Space Thruster
- Origination of Prince Oak's new alias and reasons of his change — the Eurasian Prince's newest nominal label is "Papa Eurasia"
- Anaptyx Selected Top Wireless Internet Service Provider (WISP) 2024
- Sensorium Therapeutics Highlights Promising Data on Lead Assets Targeting Anxiety & Epilepsy at Neuroscience 2024
- Mayor Brandon Johnson and World Business Chicago Lead High-level Business Mission to London, Advancing Economic Growth Opportunities for Chicago
- Bug Busters Celebrates 40 Years in the Pest Control Industry
- Made-in-the USA Manufacturer, Jeron Electronic Systems, has Experienced No Supply Delays for Shipping Nurse Call Systems and Area of Rescue Systems
- National Minority Health Association and Cell-Ed Announce Upcoming Webinar: Empowering Caregivers Through Innovative Training Programs